Primary prevention of coronary heart disease: Role of cholesterol control in the United States

Journal of Internal Medicine

Volumn 241, Issue 4, 1997, Pages 295-306

  Grundy, S M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

atherogenesis; cholesterol control; exercise; primary prevention; statins

Indexed keywords

ANTILIPEMIC AGENT;

ARTICLE; ATHEROGENESIS; CALORIC INTAKE; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; HEALTH BEHAVIOR; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

EID: 0030957805     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1997.110123000.x     Document Type: Article

References (74)

1. Sempos CT, Cleeman JI, Carroll MD, Johnson CL, Bachorik PS, Gordon DJ, Burt VL, Briefel RR, Brown CD, Lippel K, Rifkind BM. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993; 23: 3009-14
2. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89: 1329-1445.
3. Ridker PM. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. Curr Opin Lipidol 1992; 3: 285-90.
4. Cortellaro M, Boschetti C, Cofrancesco E. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombordo Atero-Thrombosi (PLAT) Study Group. Arterioscler Thromb 1992; 12: 1063-70.
5. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
6. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini J. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995; 92: 2419-25.
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wan CC, Davis BR, Braunwald E for the Cholesterol and Recurrent Events Trial Investigators. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335: 1001-3.
8. Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993; 42: 1461-7.
9. Hodis HN, Mack WJ, Azen SP. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90: 42-9.
10. Grundy SM, Wilhelmsen L, Rose R, Campbell RWF, Assman G. Coronary heart disease in high-risk populations: Lessons from Finland. Eur Heart J 1990; 11: 462-71.
11. PDAY Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA 1990; 264: 3018-24.
12. Strong JP, Oalmann MC, Malcom GT, Newman WP. McMahon CA. The Pathological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Pathobiological determinants of atherosclerosis in youth (PDAY): the rationale, methodology, and selected risk factor findings. Cardiovasc Risk Factors 1992; 2: 22-30.
13. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques. Role of extracellular lipid, macrophages, and smooth muscle cell content. Br Heart J 1993; 69: 377-81.
14. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation 1994; 90: 775-8.
15. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
16. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmson L, Wedel H, Pyorala K, Miettinen T, Haghfelt t, Faergeman O, Thorgeirson G, Jonsson B, Schwartz JS. Cholesterol lowering and use of health care resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1796-802.
17. Shepherd J, Cobbe SM, Ford I, Isles Cg, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
18. Denke MA, Grundy SM. Hypercholesterolemia in the elderly: resolving the treatment dilemma. Ann Intern Med 1990; 112: 780-92.
19. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis 1993; 104: 159-71.
20. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med 1995; 332: 1491-8.
21. Vega GL, Grundy SM. Management of primary mixed hyperlipidemia with lovastatin. Arch Int Med 1990; 150: 1313-19.
22. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 1988; 109: 25-32.
23. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13: 153-69.
24. Wingard DL, Barrett-Connor E: Heart disease and diabetes, in Diabetes in America. Bethesda. NIH/NIDDKD, 1995; 429-48.
25. Grundy SM, Barrett-Connor E, Rudel LL, Miettinen T, Spector AA. Workshop on the impact of dietary cholesterol on plasma lipoproteins and atherogenesis. Arteriosclerosis 1988; 8: 95-101.
26. Stamler J, Shekelle R. Dietary cholesterol and human coronary heart disease: the epidemiological evidence. Arch Pathol Lab Med 1988; 112: 1032-40.
27. Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med 1990; 323: 439-45.
28. Grundy SM. Lipids, nutrition, and coronary heart disease. In: [Fuster V, Ross R, Topol EJ, eds.] Philadelphia: Lippincott-Raven Publishers, 1996; 45-68.
29. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I-analysis of observational data among populations. Br Med J 1991; 302: 811-15.
30. Frost CD, Law MR, Wald NJ. By how much does dietary salt reduction lower blood pressure? II. Analysis of observational data within populations. Br Med J 1991; 302: 815-18.
31. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III. Analysis of data from trials of salt reduction. Br Med J 1991; 302: 819-24.
32. Stokes JIII, Kannel WB, Wolf PA, Cupples LA. D'Agostino RB. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 1987; 75: V65-V73.
33. Blair SN, Kohl HWIII, Paffenbarger RSJr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality: a prospective study of healthy men and women. JAMA 1989; 262: 2395-401.
34. Fletcher GF, Blair SN, Blumenthal J. Benefits and recommendations for physical activity programs for all Americans: a statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology. Circulation 1992; 86: 340-44.
35. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990; 132: 612-28.
36. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991; 53: 326S-34S.
37. Riemersma RA, Wood DA, MacIntyre CL, Elton R, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamin A. C. E and carotene. Lancet 1991; 337: 1-5.
38. Jialal I, Vega GL, Grundy SM. Physiologic levels of ascorbate inhibit the oxidative modification of low density lipoprotein. Atherosclerosis 1990; 82: 185-91.
39. Jialal I, Grundy SM. Preservation of the endogenous anti-oxidants in low density lipoprotein by ascorbate but not probucol during oxidative modification. J Clin Invest 1991: 87: 597-601.
40. Jialal I, Grundy SM. Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low density lipoprotein. J Lipid Res 1992; 33: 899-906.
41. Kang SS, Wong PW, Norosis M. Homocysteinemia due to folate deficiency. Metabolism 1987; 36: 458-62.
42. Kang SS, Wong PW, Malinow MR. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 1992; 12: 183-236.
43. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996; 275: 1893-6.
44. Denke MA, Grundy SM. Efficacy of low-dose cholesterol lowering drug therapy in men with moderate hypercholesterolemia. Arch Intern Med 1995; 155: 393-9.
45. Martin-Jadraque R, Tato F, Mostaza JM, Vega GL, Grundy SM. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Intern Med 1996; 156: 1081-8.
46. Arca M, Vega GL, Grundy SM. Hypercholesterolemia in postmenopausal women: metabolic defects and response to low-dose lovastatin. JAMA 1994; 271: 453-9.
47. National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. Circulation 1991; 83: 2154-232.
48. Grundy SM, Bilheimer D, Blackburn H, Brown WV, Kwiterovich PO, Jr., Mattson F, Schonfeld G, Weidman WH. Rationale of the diet-heart statement of the American Heart Association. Report of Nutrition Committee. Circulation 1982: 65: 839A-854A.
49. Moser M, Hebert P, Hennekens C. An overview of the meta-analysis of the hypertension treatment trials. Arch Intern Med 1991; 151: 1277-9.
50. Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM, eds. Hypertension, Pathophysiology, Diagnosis, and Management. New York: Raven Press, 1995; 253-70.
51. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994; 308: 367-73.
52. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham Study. Ann Intern Med 1971; 74: 1-12.
53. Rossouw JE. Clinical trials of cholesterol lowering drugs. In: Rifkind BM, ed. Drug Treatment of Hyperlipidemia, New York: Marcel Dekker Inc., 1991; 67-88.
54. National Research Council, Diet and Health: Implications for Reducing Chronic Disease Risk. Washington, DC: National Academy Press, 1989.
55. US Department of Health and Human Services Public Health Service. The Surgeon General's Report on Nutrition and Health. Bethesda. MD: DHHS (PHS) Publications, 1988; 88-215.
56. US Department of Agriculture/Department of Health and Human Services. Nutrition and Your Health: Dietary Guidelines for Americans, edn 232. Home and Gorden Bulletin, 1990.
57. Centers for Disease Control and Prevention. Daily dietary fat and total food energy intakes. Third National Health and Nutrition Examination Survey. Phase 1. Morbidity and Mortality Weekly Report 1994; 43: 116-25.
58. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, Gorden DJ, Burt VL, Brown CD, Lippel K, Cleeman JI. Declining serum total cholesterol levels among US adults: The National Health and Nutrition Examination Surveys. JAMA 1993; 269: 3002-8.
59. Najjar MF, Rowland M. Anthropometric reference data and prevalence of overweight, United States, 1976-080. Vital and Health Statistics Series 11, no. 238. DHHS Publication No. (PHS) 87-168.S. Hyattsville, MD: Department of Health and Human Services, National Center for Health Statistics.
60. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960-1991. JAMA 1994; 273: 205-11.
61. Federation of American Societies for Experimental Biology, Life Sciences Research Office. Third report on nutrition monitoring in the United States, Vol. S. Washington DC: Interagency Board for Nutrition Monitoring and Related Research. Government Printing Office, 1995.
62. Chung CS, Villafuerte A, Wood DW, Lew R. Trends in prevalences of behavioral risk factors: recent Hawaiian experience. Am J Public Health 1992; 82: 1544-6.
63. Piani AL, Schoenborn CA. Health promotion and disease prevention: United States, 1990. Vital and Health Statistics Series 10, No. 185. DHHS Publication No. (PHS) 93-151.S. Hyattsville, MD: Department of Health and Human Services, National Center for Health Statistics, 1993.
64. Kuskowska-Wolk A, Karlsson P, Stolt M, Rossner S. The predictive validity of body mass index based on self-reported weight and height, Int J Obesity 1989; 13: 441-53.
65. Rowland ML. Self-reported weight and height. Am J Clin Nutr 1990; 52: 1125-33.
66. Schoenborn CA. Health promotion and disease prevention, United States, 1985. Vital and Health Statistics Series 10, No. 16.S. Hyattsville, MD: Department of Health and Human Services, National Center for Health Statistics, 1985.
67. Schoenborn CA. Findings from the National Health Interview Survey. Evaluation and the Health Professions 1987; 10: 438-59.
68. Shah M, Hannan PJ, Jeffery RW. Secular trend in body mass index in the adult population of three communities from the upper mid-western part of the USA; the Minnesota Heart Health Program. Int J Obesity 1991; 15: 499-503.
69. Garrison RJ, Kannel WB. A new approach for estimating healthy body weights. Int J Obesity 1993; 17: 417-23.
70. Visser M, Deurenberg P, van Staveren WA, Hautvast JG. Resting metabolic rate and diet-induced thermogenesis in young and elderly subjects; relationship with body composition, fat distribution, and physical activity level. Am J Clin Nutr 1995; 61: 772-8.
71. Tzankoff SP, Norris AH. Longitudinal changes in basal metabolism in man. J Applied Physiol 1978; 45: 536-9.
72. Poehlman ET, Toth MJ. Mathematical ratios lead to spurious conclusions regarding age-and sex-related differences in resting metabolic rate. Am J Clin Nutr 1995; 61: 482-5.
73. Poehlman ET, Berke EM, Joseph JR, Gardner AW, Katzman-Rooks SM, Goran MI. Influence of aerobic capacity, body composition, and thyroid hormones on the age-related decline in resting metabolic rate. Metabolism: Clinical & Experimental 1992; 41: 915-21.
74. Poehlman ET. Regulation of energy expenditure in aging humans. J Am Geriatrics Soc 1993; 41: 552-59.